IQVIA

Last updated
IQVIA Holdings, Inc.
Company type Public
Industry Contract Research Organization
Pharmaceutical Service, AI, IT, Consulting
Founded1982;43 years ago (1982)
Founder Dennis Gillings
Headquarters Durham, North Carolina, U.S.
Key people
Ari Bousbib
(Chairman & CEO)
ProductsStrategy & Operation Consulting, Support services for pharmaceutical, biotech and medical companies and individuals
RevenueIncrease2.svg US$15.4 billion (2024)
Increase2.svgUS$2.20 billion (2024)
Increase2.svgUS$1.37 billion (2024)
Total assets Increase2.svgUS$26.9 billion (2024)
Total equity Decrease2.svgUS$6.07 billion (2024)
Number of employees
c.88,000 (2024)
Website iqvia.com
Footnotes /references
[1]

IQVIA Holdings, Inc., headquartered in Durham, North Carolina, is an American company focused on health information technology and clinical research.

Contents

The company operates three divisions: Technology & Analytics (40% of 2024 revenues), focused on health information technology with access to 1.2 billion unique non-identified patient records globally, offers cloud-based customer relationship management application software as well as analytics consulting services all to the healthcare industry; Research & Development (55% of 2024 revenues), which is a contract research organization that handles all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, post-approval services, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics; and Contract Sales & Medical (5% of 2024 revenues), which offers contract sales to healthcare providers and patient engagement services. [1]

The company is ranked 282nd on the Fortune 500 [2] and 680th on the Forbes Global 2000. [3]

The company has been criticized for collecting and selling patient medical records even though the data is anonymized.

IQVIA was formed in 2016 from the merger of Quintiles, a contract research organization, and IMS Health, a healthcare data and analytics provider and the largest vendor of U.S. physician prescribing data. [4] [5] [6] The IQVIA name is a combination of: I (IMS Health), Q (Quintiles), and VIA (by way of).

History

IMS Health

The original name of the company was Intercontinental Marketing Statistics, hence the IMS name. IMS Health's corporate headquarters is located in Danbury, Connecticut, United States. The company's chairman and CEO is Ari Bousbib.

Quintiles

Quintiles was the world's largest provider of biopharmaceutical development and commercial outsourcing services. The company offered clinical data management, clinical trial execution services, pharmaceuticals, drug development, financial partnering, and commercialization expertise to companies in the biotechnology, pharmaceutical and healthcare sectors.

In 1982, Dennis Gillings founded and incorporated Quintiles Transnational in North Carolina. [21] Quintiles Transnational established Quintiles Pacific Inc. and Quintiles Ireland Ltd. in 1990. [22] In 1991 Quintiles GmbH was established in Germany and Quintiles Laboratories Ltd. was established in Atlanta, Georgia. [23] In September 1996, Quintiles purchased Innovex Ltd. of Britain for $747.5 million in stock. [24] Quintiles went public in 1997 and completed a successful secondary stock offering. [25]

Merger of IMS Health and Quintiles

In October 2016, Quintiles merged with IMS Health to form QuintilesIMS. [5] [26] [27] [28] [29] In November 2017, the company adopted the new name of IQVIA.

Controversies

IMS Health's business of collecting and selling pharmaceutical sales data, even though it is anonymized, was under scrutiny from both the media and the legal system. [30]

IMS Health v. Ayotte was a free speech case involving IMS Health. [31] [32] [33]

Sorrell v. IMS Health Inc. was a case about physician-data privacy, which went to the U.S. Supreme Court. The High Court ruled in favor of the company. [34] [35] [36] [37]

IQVIA was contracted by the UK government's Office of National Statistics to provide data on the prevalence of COVID-19 infection in the population. Some users of the survey reported problems contacting IQVIA and arranging for testing. [38] The problems with how the survey results were collected were criticised for potentially leading to biased data by New Scientist. [39]

On July 17, 2023, the Federal Trade Commission sued to block IQVIA’s acquisition of Propel Media alleging in an administrative complaint that the acquisition would give IQVIA a market-leading position in health care programmatic advertising and would raise health-care prices for consumers. In December 2023, U.S. District Court Judge Edgardo Ramos issued an order granting the FTC’s motion for preliminary injunction to block the merger. Speaking in favor of the FTC, Ramos said, "The FTC has shown that there is a reasonable probability that the proposed acquisition will substantially impair competition in the relevant market and that the equities weigh in favor of injunctive relief." An administrative trial was scheduled to start on January 18, 2024. [40] [41] [42] However, on January 5, 2024, IQVIA and Propel Media announced that they had mutually agreed to abandon the proposed merger. [43]

References

  1. 1 2 "IQVIA Holdings, Inc. 2024 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 13, 2025.
  2. "Fortune: IQVIA" . Fortune.
  3. "Forbes: IQVIA". Forbes .
  4. 1 2 Steinbrook, R (Jun 29, 2006). "For sale: physicians' prescribing data". The New England Journal of Medicine. 354 (26): 2745–7. doi:10.1056/nejmp068125. PMID   16807410.
  5. 1 2 Henderson, Jennifer (3 October 2016). "Quintiles, IMS Health complete merger" . American City Business Journals .
  6. Liu, Angus (November 8, 2017). "QuintilesIMS no more. Say hello to IQVIA". Fierce Biotech .
  7. "The Business Week 50" Bloomberg Business Week, Accessed 20 October 2010
  8. "TPG and Pension Plan to Buy IMS Health" New York Times Deal Book, 5 November 2009
  9. Leuty, Ron (24 April 2012). "IMS Health to buy clinical trials software company Decision View". San Francisco Business Times. Retrieved 2020-11-16.
  10. Conn, Joseph (2012-08-15). "IMS acquires analytics company TTC". Modern Healthcare. Retrieved 2020-11-16.
  11. "IMS Health Expands Suite of Syndicated, Web-based Analytics With Acquisition of PharmaDeals Ltd". FiercePharma. 14 August 2012. Retrieved 2020-11-16.
  12. "IMS Health Acquires Dataline Software, Extending Real-World Evidence Technology Platform and Application Suite". IMS Health. 2015-11-11. Retrieved 2017-05-25.
  13. "Cegedim completes disposal of the CRM and Strategic Data Division to IMS Health" (PDF). 1 April 2015.
  14. "Acquisition announcement" (PDF).
  15. "Quintiles is merging with IMS in a deal worth about $9 billion - Fortune". Fortune. Reuters. 3 May 2016.
  16. "Quintiles, IMS Health Plan $9B Merger". GEN. 3 May 2016.
  17. Kristen Hallam; Zachary Tracer (3 May 2016). "IMS Health to Buy Quintiles in $9 Billion Pharma Data Deal". Bloomberg.com.
  18. Erik Holm (3 May 2016). "Deals of the Day: IMS Health Merges With Quintiles, Biogen to Spin Off Hemophilia Arm". WSJ.
  19. Henderson, Jennifer (3 October 2016). "Quintiles, IMS Health complete merger". Triangle Business Journal, American City Business Journals. Retrieved 3 October 2016.
  20. "QuintilesIMS is now IQVIA". Business Wire. 6 November 2017. Retrieved 6 November 2017.
  21. Matthew Herper (November 22, 2010). "Money, Math and Medicine". Forbes Magazine. Retrieved July 21, 2011.
  22. "Quintiles Pacific, Inc.: Private Company Information - Businessweek". Bloomberg News .
  23. "Quintiles Laboratories Limited: Private Company Information - Businessweek". Bloomberg News .
  24. Derdak T, Atkins W (2005). "Quintiles Transnational Corp". Encyclopedia.com.
  25. Olivia Oran (9 May 2013). "Quintiles IPO raises more-than-planned $947 million as stocks rally". Reuters.
  26. "Quintiles is merging with IMS in a deal worth about $9 billion". Fortune . Reuters. 3 May 2016.
  27. "Quintiles, IMS Health Plan $9B Merger". Genetic Engineering and Biotechnology News . 3 May 2016.
  28. Hallam, Kristen; Tracer, Zachary (3 May 2016). "IMS Health to Buy Quintiles in $9 Billion Pharma Data Deal" . Bloomberg News .
  29. Holm, Erik (3 May 2016). "Deals of the Day: IMS Health Merges With Quintiles, Biogen to Spin Off Hemophilia Arm" . The Wall Street Journal .
  30. Tanner, Adam (January 6, 2014). "Company that Knows What Drugs Everyone Takes Going Public" . Forbes .
  31. Baxter, Alexander D. "IMS Health v. Ayotte: A New Direction on Commercial Speech Cases" (PDF). Berkeley Technology Law Journal . 25 (1): 649–670. Archived from the original (PDF) on 5 November 2010. Retrieved 5 February 2014.
  32. Shapiro, Ilya (28 April 2009). "IMS Health v. Ayotte | Cato Institute". cato.org. Cato Institute . Retrieved 5 February 2014.
  33. Bibet-Kalinyak, Isabelle (2012). "Critical Analysis of Sorrell v. IMS Health, Inc.: Pandora's Box at Best". Food & Drug L.J. 67 (2): 191–241, ii. PMID   24620419.
  34. "IMS Health Wins Court Attack on Vermont Marketing Law". Bloomberg. 23 November 2010.
  35. Law360 11 August, 2011. Inside Sorrell V. IMS Health
  36. Adam Liptak for the New York Times. 23 June 2011 Drug Makers Win Two Supreme Court Decisions
  37. Gayland Hethcoat Regulating Pharmaceutical Marketing After Sorrell v. IMS Health Inc. Quinnipiac Health Law Journal. 2012 Vol. 15:187
  38. Vaughan, Adam. "UK's vital covid-19 infection tracking survey deluged by complaints". New Scientist. Retrieved 2021-07-13.
  39. Vaughan, Adam. "UK's official statisticians had concerns over covid-19 survey bias". New Scientist. Retrieved 2021-07-13.
  40. "Statement on FTC Win Securing Temporary Block of IQVIA's Acquisition of Propel Media". Federal Trade Commission. 2024-01-03. Retrieved 2024-01-19.
  41. "IQVIA Drops as FTC Temporarily Blocks Its Acquisition of Propel Media". Investopedia. Retrieved 2024-01-19.
  42. "FTC Gets Court Backing to Halt IQVIA's Purchase of Propel Media". news.bloomberglaw.com. Retrieved 2024-01-19.
  43. "IQVIA Drops Plan to Purchase Propel Media After FTC Injunction". news.bloomberglaw.com. Retrieved 2024-03-18.